You are here

Satellite Symposium at the European Society for Medical Oncology 2016 Congress

Monday 10 October 2016, 18:30–20:00 Copenhagen, Denmark

Progress in the treatment of advanced breast cancer: spotlight on selective CDK4&6 inhibitors

Educational need

Clinicians have an unmet need to understand the mechanisms underlying CDK4&6 inhibition, the rationale for using CDK4&6 inhibitors to treat advanced breast cancer, and the clinical data supporting the use of CDK4&6 inhibitors in the treatment of advanced breast cancer.

Learning objectives

Following this highly interactive symposium on the use of CDK4&6 inhibitors in the treatment of advanced breast cancer, attendees will be able to:

  • Recognize that selective CDK4&6 inhibitors, in contrast to previous non-selective inhibitors, are an effective treatment option for patients with HR+/HER2− breast cancer
  • Describe the underlying mechanisms of CDK4&6 inhibition in breast cancer treatment
  • Discuss the current clinical evidence for CDK4&6 inhibitors as therapy for HR+/HER2− breast cancer
  • Explain how CDK4&6 inhibitors can potentially improve breast cancer management
  • Recognize the importance of identification of patients who will benefit, including the need for suitable biomarkers, and discuss possible combination-therapy strategies
  • Describe factors that are important from the patient’s perspective, and explain how CDK4&6 inhibitors might address these patient needs


18:30 - 18:35 Welcome and introduction

Fatima Cardoso (Lisbon, Portugal)

18:35 - 18:55 Lessons learned from the past: CDK4&6 inhibition over time

Angelo Di Leo (Prato, Italy)

18:55 - 19:15 Current insights: CDK4&6 inhibitors as a therapeutic option for HR+/HER2− breast cancer

Fatima Cardoso (Lisbon, Portugal)

19:15 - 19:35 Patients’ views: potential improvement through CDK4&6 inhibition

Naomi Fitzgibbon (Dublin, Ireland) and Angelo Di Leo (Prato, Italy)

19:35 - 19:55 Future perspectives: implications of the use of CDK4&6 inhibitors  on breast cancer

Moderator: Lesley-Ann Martin (London, UK)

Panel: Fatima Cardoso (Lisbon, Portugal), Angelo Di Leo (Prato, Italy), Naomi Fitzgibbon (Dublin, Ireland)

19:55 - 20:00 Summary and key learning points

Fatima Cardoso (Lisbon, Portugal)

About the speakers

Fatima Cardoso, MD

Fatima Cardoso is Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal.

Angelo Di Leo, MD, PhD

Angelo Di Leo is currently Head of the Sandro Pitigliani Medical Oncology Unit, and Chair of the Oncology Department, at the Hospital of Prato...

Naomi Fitzgibbon, Msc

Naomi Fitzgibbon is Cancer Information Service Manager at the Irish Cancer Society in Dublin, Ireland.

Lesley-Ann Martin, MD

Lesley-Ann Martin is Senior Staff Scientist and Group Leader within the Breast Cancer Now Tony Robins Research Centre...

Register for the E-Alert


We would like to know what challenges you face in treating patients with advanced breast cancer.

Send us your feedback and take this opportunity to submit your questions to our faculty.

Made possible by an educational grant from